Objectives: to describe the clinical and paraclinical profile of our population with spondyloarthritis and to investigate factors associated with active and severe disease.
Methods: A retrospective observational study, conducted in the rheumatology department at CHU Hassan II of Fez, analyzing the records of patients diagnosed as spondylarthritis during the period extending from January 2009 to June 2014. Patients having a spondyloarthritis associated with intestinal bowel disease and psoriasis, as well as reactive arthritis were excluded.
Results: we included 136 patients (86 men and 50 women, the mean age was 38.06 ± 13.46 years, diagnostic delay was 6 years and 3 months). Patients with the HLA-B27 allele numbered 7. The clinical symptomatology was dominated by axial involvement in 92.6% of cases, followed by peripheral damage in 35.3% of cases and entheseal involvement in 30.1% of cases. Uveitis was the most common extra-articular manifestation in 18.4% of cases. 54% of patients had active disease, 53% had disease with functional impairment, and 34% had severe disease.10.3% of patients had juvenile-onset, 24.1% patients had a coxitis. We didn't find a significant association between sanitation (availability of drinking water and the use of refrigerator) the diagnosis delay, HLA-B27 allele, smoking, and activity and severity disease. A significant association was found between the presence of coxitis and male sex (p = 0.005).
Conclusion: spondyloarthritis in our population still suffers from a delayed diagnosis with the frequency of active and severe forms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/1573397113666170406125338 | DOI Listing |
Curr Rheumatol Rep
December 2024
Department of Medicine, Division of Rheumatology, Queen's University, Kingston, ON, Canada.
Purpose Of Review: The canonical pathogenesis of spondyloarthritis (SpA) involves inflammation driven by HLA-B27, type 3 immunity, and gut microbial dysregulation. This review based on information presented at the SPARTAN meeting highlights studies on the pathogenesis of SpA from the past year, focusing on emerging mechanisms such as the roles of microbe-derived metabolites, microRNAs (miRNAs) and cytokines in plasma exosomes, specific T cell subsets, and neutrophils.
Recent Findings: The induction of arthritis in a preclinical model through microbiota-driven alterations in tryptophan catabolism provides new insights as to how intestinal dysbiosis may activate disease via the gut-joint axis.
BMC Med Res Methodol
December 2024
Janssen Research & Development LLC, Global Epidemiology Organization, Raritan, NJ, USA.
Background: Autoimmune disorders have primary manifestations such as joint pain and bowel inflammation but can also have secondary manifestations such as non-infectious uveitis (NIU). A regulatory health authority raised concerns after receiving spontaneous reports for NIU following exposure to Remicade, a biologic therapy with multiple indications for which alternative therapies are available. In assessment of this clinical question, we applied validity diagnostics to support observational data causal inferences.
View Article and Find Full Text PDFJ Pers Med
November 2024
Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rom Tor Vergata, 00133 Rome, Italy.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases affecting the spine and peripheral joints, causing pain, stiffness, and reduced mobility. This narrative review examines how lifestyle factors-specifically smoking, alcohol consumption, and unhealthy diet-contribute to the onset and progression of SpA. It highlights their impact on disease activity, comorbidities, radiographic damage, and treatment response.
View Article and Find Full Text PDFAutoimmunity
December 2025
Spine Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Ankylosing Spondylitis (AS) and Systemic Sclerosis (SSc) are both autoimmune diseases, albeit with distinct anatomical targets. AS primarily affects the spine and sacroiliac joints, triggering inflammation and eventual fusion of the vertebrae. SSc predominantly impacts the skin and connective tissues, leading to skin fibrosis, thickening, and potential damage to vital organs such as the lungs, heart, and kidneys.
View Article and Find Full Text PDFJ Pharm Technol
December 2024
Rheumatology Department, Hospital de Sagunto, Port de Sagunt, Spain.
Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Retrospective cohort study that used registries and medical records from a single hospital (June 2022 to April 2024). Adult patients with RA, PsA, and axSpA treated with adalimumab biosimilar MSB11022 who switched to biosimilar GP2017 were identified and followed up until April 2024, or disenrollment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!